Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price

INBXStock

$122.72+319.76%52W

Market Cap$1.81B

P/E0.55x

PEG Ratio—

Div yield—

Beta3.08

INBX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)17.39%

Price vs S&P 500 (4W)28.65%

VGM Score50.00

P/E Ratio (Annual)0.55x

Book Value / Share (Quarterly)$0.55

P/TBV (Annual)16.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.98%

Cash Flow / Share (Quarterly)$-4.67

Price vs S&P 500 (YTD)20.88%

Net Profit Margin (TTM)-5465.64%

EPS (TTM)$-8.39

10-Day Avg Trading Volume0.27M

EPS Excl Extra (TTM)$-8.39

Revenue Growth (5Y)-36.79%

EPS (Annual)$-9.04

ROI (Annual)-129.02%

Net Profit Margin (5Y Avg)162369.51%

Cash / Share (Quarterly)$11.07

P/E Normalized (Annual)0.55x

ROA (Last FY)-95.62%

Revenue Growth TTM (YoY)550.00%

EBITD / Share (TTM)$-7.74

ROE (5Y Avg)-289.99%

Operating Margin (TTM)-5522.64%

Cash Flow / Share (Annual)$-8.91

P/B Ratio178.06x

P/B Ratio (Quarterly)143.75x

Net Income / Employee (Annual)$-1,284,900

EV / Revenue (TTM)1026.13x

Net Interest Coverage (TTM)-29.14x

ROA (TTM)-72.32%

EV / EBITDA (TTM)0.83x

EPS Incl Extra (Annual)$-9.04

Current Ratio (Annual)3.93x

Quick Ratio (Quarterly)6.10x

3-Month Avg Trading Volume0.40M

52-Week Price Return319.76%

Revenue / Employee (TTM)$11,900

Tangible BV / Share (Quarterly)$2.74

P/S Ratio (Annual)1094.81x

Asset Turnover (Annual)0.01x

52-Week High$155.29

Operating Margin (5Y Avg)163102.06%

EPS Excl Extra (Annual)$-9.04

CapEx CAGR (5Y)-53.09%

26-Week Price Return28.63%

Quick Ratio (Annual)3.68x

13-Week Price Return-5.09%

Total Debt / Equity (Annual)12.58x

Current Ratio (Quarterly)6.46x

Enterprise Value$1.44B

Revenue / Share Growth (5Y)-24.49%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-22.81%

Revenue / Employee (Annual)$11,900

Pretax Margin (Annual)-10773.31%

Cash / Share (Annual)$8.52

3-Month Return Std Dev57.98%

Net Income / Employee (TTM)$-1,194,400

ROE (Last FY)-1752.22%

Net Interest Coverage (Annual)-18.18x

EPS Basic Excl Extra (Annual)$-9.04

Receivables Turnover (TTM)4.96x

Total Debt / Equity (Quarterly)12.58x

EPS Incl Extra (TTM)$-8.39

Receivables Turnover (Annual)0.33x

ROI (TTM)-92.41%

P/S Ratio (TTM)1016.61x

Pretax Margin (5Y Avg)162387.96%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$1.33

Price vs S&P 500 (52W)301.45%

Year-to-Date Return32.84%

5-Day Price Return10.91%

EPS Normalized (Annual)$-9.04

ROA (5Y Avg)131.05%

Net Profit Margin (Annual)-10773.46%

Month-to-Date Return27.90%

Cash Flow / Share (TTM)$-4.22

EBITD / Share (Annual)$-8.56

Operating Margin (Annual)-10386.54%

LT Debt / Equity (Annual)12.58x

ROI (5Y Avg)183.11%

LT Debt / Equity (Quarterly)12.58x

EPS Basic Excl Extra (TTM)$-8.39

P/TBV (Quarterly)7.50x

P/B Ratio (Annual)143.75x

Pretax Margin (TTM)-5465.50%

Book Value / Share (Annual)$0.55

Price vs S&P 500 (13W)-7.89%

Beta3.08x

Revenue / Share (TTM)$0.08

ROE (TTM)-269.56%

52-Week Low$24.00

vGradeD

gGradeC

mGradeB

vgmGradeC

INBX Earnings Surprise History

Q2 25-1.85est. -2.60

Q3 25-2.28est. -1.72

Q4 25-2.11est. -2.08

Q1 26-2.15est. -1.20

Q2 26-2.34est. -2.28

INBX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Inhibrx Biosciences, Inc. Common Stock

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies using its proprietary protein engineering platform. The company's pipeline includes INBRX-109 and INBRX-106, multivalent therapeutic candidates designed to optimize target engagement and agonist activity.